Genetic burden in neonatal and pediatric-onset pulmonary hypertension: A single-center retrospective study using
Chen Chen1, Hang Zhou2, Fang Fu2
1Respiratory Department, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China; Department of Prenatal Diagnostic Center, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, China.
Insights
Trio whole-exome sequencing (trio-WES) identified genetic variants in 14 children with pulmonary hypertension. This genetic testing is valuable for diagnosing pediatric pulmonary hypertension and guiding treatment decisions.
Area of Science:
- Genetics
- Pediatrics
- Cardiology
Background:
- Pulmonary hypertension (PH) in neonates and children presents diagnostic challenges.
- Identifying genetic factors is crucial for understanding PH etiology and progression.
Purpose of the Study:
- To investigate genetic factors contributing to neonatal and pediatric pulmonary hypertension in a Chinese population.
- To evaluate the diagnostic utility of trio whole-exome sequencing (trio-WES) in this cohort.
Main Methods:
- Retrospective analysis of 51 children diagnosed with PH (20 pediatric PH, 31 persistent PH of the newborn).
- Diagnosis confirmed by echocardiography and catheterization.
- Trio-WES performed on patients and their parents.
Main Results:
- Trio-WES identified 16 pathogenic/likely pathogenic variants in 10 genes in 14 patients.
- Commonly affected genes included BMPR2, CHD7, FOXF1, and TNNI3.
- Two patients had de novo pathogenic copy number variations.
Conclusions:
- Trio-WES demonstrated significant diagnostic value in pediatric pulmonary hypertension.
- The study supports the recommendation of trio-WES for diagnosing pediatric PH.
Objective:
This single-center retrospective study aimed to investigate the genetic factors contributing to neonatal and pediatric pulmonary hypertension in a Chinese population using trio whole-exome sequencing (trio-WES).
Method:
This retrospective analysis reviewed the clinical and genetic profiles of children under 18 years of age diagnosed with pulmonary hypertension between March 2017 and March 2022. The diagnosis of pediatric pulmonary hypertension was confirmed through echocardiography and catheterization. Trio-WES was performed on the patients and their parents after obtaining informed consent.
Results:
A total of 51 children with neonatal and pediatric pulmonary hypertension were included, comprising 20 with pediatric pulmonary arterial hypertension and 31 with persistent pulmonary hypertension of the newborn. Trio-WES detected 16 pathogenic or likely pathogenic variants in 14 patients across ten genes, including: BMPR2 (n = 2), CHD7 (n = 2), FOXF1 (n = 2), MED13L (n = 1), TNNI3 (n = 2), ALMS1 (n = 1), KMT2D (n = 2), NKX2-1 (n = 1), NONO (n = 1), and CACNA1E (n = 1). In addition, two patients exhibited de novo pathogenic copy number variations.
Conclusion:
Our findings demonstrate the significant diagnostic value of trio-WES in pediatric pulmonary hypertension, supporting its recommendation for these patients.
Related Concept Videos
Animal Mitochondrial Genetics
Single Nucleotide Polymorphisms-SNPs
Incomplete Dominance
Genome-wide Association Studies-GWAS
GWAS does not require the identification of the target gene involved in...


